Recent research has shown that certain forms of E. coli bacteria tend to colonize hypoxic areas of the body, including tumors, suggesting they might be playing a role in cancer therapeutics.

A new study reveals critical insights into the role of gamma-delta T cells across 33 cancer types, shedding light on their potential as clinical biomarkers and therapeutic targets in cancer treatment.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...

A new report from the American Cancer Society says deaths from the disease have fallen nearly 45% compared to 35 years ago. However, new cases continue to rise.

Rose-Anna Hoey never imagined that she would be given a cancer diagnosis, as a leading distance runner with no genetic ...

Immunotherapy biologics represent a transformative approach in treating cancer and infections by using biological molecules to strengthen the immune system’s response. Biologics such as monoclonal ...

Elicera Therapeutics describes how CAR T cells armed with neutrophil-activatingprotein can improve cancer therapy by inducing ...

A new form of cancer treatment for melanoma patients has been approved by the FDA, after a clinical trial in St. Louis showed ...

A new trial highlights that the timing of chemoradiation and immunotherapy is crucial when treating limited-stage small cell ...

Thanks to early detection through widespread screening and dramatic breakthroughs in immunotherapy and other cancer ...

Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on BriaCell Therapeutics (BCT – Research Report). The associated ...

Researchers at the Spanish National Cancer Research Centre (CNIO) propose a new treatment for brain metastases that respond poorly, or not at all, to immunotherapy, and provide a biomarker to predict ...